$HGSI News

Last published 12y ago

12y agoASDN HGSI HLS VG+26Pershing Square Proposes Independent Slate For Allergan Board of DirectorsBusiness WireNEW YORK--(BUSINESS WIRE)--Pershing Square Capital Management, L.P. (“Pershing Square”) today announced a slate of six highly experienced, independent directors for the board of directors of Allergan, Inc. (“Allergan”). The six members of the slate are: Betsy Atkins, Cathleen P. Black, Fredric N. Eshelman, Steven J. Shulman, David A. Wilson and John J. Zillmer.
14y agoHGSIRyan & Maniskas, LLP Announces Investigation of Human Genome Sciences Inc.Business WireWAYNE, Pa.--(BUSINESS WIRE)--Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/hgsi) is investigating potential claims against the board of directors of Human Genome Sciences Inc. (“Human Genome” or the “Company”) (NASDAQ: HGSI) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell Human Genome to GlaxoSmithKline plc in a transaction value ...
14y agoHGSI GSKRobbins Umeda LLP Announces an Investigation of Human Genome Sciences, Inc.Business WireSAN DIEGO--(BUSINESS WIRE)--Shareholder rights firm Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of the law by members of the board of directors of Human Genome Sciences (NASDAQ: HGSI) in connection with their efforts to sell the company to GlaxoSmithKline plc (NYSE: GSK). Concerned shareholders who would like more information about ...
14y agoHGSIGSK to acquire Human Genome Sciences for US$14.25 per share in cashBusiness WireLONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE: GSK) and Human Genome Sciences (NASDAQ: HGSI) today announced that the companies have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. The transaction values HGS at approximately US$3.6 billion on an equity basis, or approximately US$3 billion net of cash and debt, and represents a premium of 99% ...
14y agoHGSIFYI From Human Genome Sciences: GlaxoSmithKline Announces Positive Data from Harmony 8 Phase 3 Trial and Completion of Clinical Registration Package for Albiglutide in Type 2 DiabetesBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Attached is a press release issued earlier today by GlaxoSmithKline, announcing that data have been received from the Phase 3 Harmony 8 study and from the event-driven meta-analysis for assessment of cardiovascular safety conducted across the albiglutide clinical program in type 2 diabetes. These data are the final elements required to complete the clinical registr ...
14y agoHGSIHuman Genome Sciences Announces Resubmission of Raxibacumab BLA to FDABusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for raxibacumab, a treatment for inhalational anthrax, and has established December 15, 2012 as the Prescription Drug User Fee Act (PDUFA) action date.
14y agoHGSIHuman Genome Sciences Responds To GSK Extension of Unsolicited Tender OfferBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today issued the following statement regarding the extension by GlaxoSmithKline plc (GSK) of its unsolicited tender offer to acquire all the outstanding common shares of HGS at a price of $13.00 per share in cash and GSK’s statement that approximately 375,526 shares of HGS common stock have been tendered into their offer. ...
14y agoHGSIREPEAT/Human Genome Sciences Announces July 16 as the Date for Submission of Definitive Acquisition ProposalsBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that, in connection with its ongoing strategic alternative review process, it had previously set a bid date of July 16, 2012 for the submission of definitive proposals to acquire all outstanding common shares of HGS. In this regard, HGS yesterday sent a letter to GlaxoSmithKline (GSK) once again inviting GS ...
14y agoHGSIHuman Genome Sciences Announces July 16 as the Date for Submission of Definitive Acquisition ProposalsBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that, in connection with its ongoing strategic alternative review process, it had previously set a bid date of July 16, 2012 for the submission of definitive proposals to acquire all outstanding common shares of HGS. In this regard, HGS yesterday sent a letter to GlaxoSmithKline (GSK) once again inviting GS ...
14y agoHGSIFYI from Human Genome Sciences: GlaxoSmithKline Announces New Data from Phase 3 Studies of Once-Weekly Albiglutide in Type 2 DiabetesBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that detailed findings from the Harmony 6 Phase 3 study comparing albiglutide to prandial insulin (Lispro), were presented today at the American Diabetes Association Meeting (ADA) in Philadelphia, USA, and show that the effect is maintained out to 52 weeks. Results from the Harmo ...
14y agoHGSIHuman Genome Sciences Responds to GSK Extension of Unsolicited Tender OfferBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today issued the following statement regarding the extension by GlaxoSmithKline plc (GSK) of its unsolicited tender offer to acquire all the outstanding common shares of HGS at a price of $13.00 per share in cash and GSK’s statement that approximately 474,029 shares of HGS common stock have been tendered into their offer. ...
14y agoHGSIHuman Genome Sciences Announces Multiple Abstracts Related to BENLYSTA® and Systemic Lupus Erythematosus to Be Presented at the 2012 EULAR Annual European Congress of RheumatologyBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that several abstracts related to BENLYSTA® (belimumab) and systemic lupus erythematosus (SLE) will be presented at the EULAR Annual European Congress of Rheumatology, being held in Berlin, Germany from June 6 to June 9, 2012. A total of seven abstracts – all posters – have been accepted for presentation, f ...
14y agoHGSIHuman Genome Sciences Invites Investors to Listen to Webcast of Presentation at Goldman Sachs ConferenceBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the Goldman Sachs 33rd Annual Global Healthcare Conference will be webcast and may be accessed at www.hgsi.com.
14y agoHGSIHuman Genome Sciences Response to GSK Press ReleaseBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today issued the following statement in response to the GlaxoSmithKline plc (GSK) announcement regarding expiration of the Hart-Scott-Rodino waiting period:
14y agoHGSIHuman Genome Sciences Announces Adoption of Short-Term Stockholder Rights PlanBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (NASDAQ: HGSI) (“HGS” or the “Company”) announced today that its Board of Directors has adopted a Stockholder Rights Plan (the “Rights Plan”) and declared a dividend of one share purchase right (a “Right”) for each share of HGS’s common stock (the “Common Stock”) held of record at the close of business on May 29, 2012.
14y agoHGSIHuman Genome Sciences Board of Directors Unanimously Determines GlaxoSmithKline Unsolicited Tender Offer is Inadequate and Not in the Best Interests of StockholdersBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that its Board of Directors, after careful review and consideration with the assistance of the Company’s management and financial and legal advisors, has unanimously determined that the unsolicited tender offer from GlaxoSmithKline (“GSK”) to acquire all outstanding common shares of HGS for $13.00 per share ...
14y agoHGSIHuman Genome Sciences Board of Directors to Review Unsolicited Tender Offer From GlaxoSmithKlineBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today confirmed that GlaxoSmithKline plc (GSK) has announced its intention to commence an unsolicited tender offer to acquire all the outstanding common shares of HGS at a price of $13.00 per share in cash.
14y agoHGSIHuman Genome Sciences Announces First Quarter 2012 Financial ResultsBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial results for the quarter ended March 31, 2012, and provided recent highlights.
14y agoHGSIHuman Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2012 Financial ResultsBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that it will sponsor a conference call to discuss its financial results for the quarter ended March 31, 2012. These results are expected to be disclosed on Tuesday, April 24, 2012, after the capital markets close.
14y agoHGSIHuman Genome Sciences Announces Unsolicited Offer from GlaxoSmithKline; HGS Board of Directors Authorizes Exploration of Strategic AlternativesBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has received an unsolicited proposal from GlaxoSmithKline plc (GSK) to acquire HGS for $13.00 per share in cash.
14y agoHGSIFYI from Human Genome Sciences: GlaxoSmithKline Announces Further Data from Phase 3 Trials of AlbiglutideBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that topline results have been received from seven of the eight Harmony Phase 3 studies investigating the use of albiglutide in type 2 diabetes.
14y agoHGSIHuman Genome Sciences Invites Investors to Listen to Webcast of Presentation at Barclays Capital ConferenceBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the Barclays Capital 2012 Global Healthcare Conference will be webcast and may be accessed at www.hgsi.com.
14y agoHGSIHuman Genome Sciences Invites Investors to Listen to Webcast of Presentation at Cowen and Company ConferenceBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the Cowen & Company 32nd Annual Healthcare Conference will be webcast and may be accessed at www.hgsi.com.
14y agoHGSIHuman Genome Sciences Announces Fourth-Quarter and Full-Year Financial Results and Key DevelopmentsBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial results for the quarter and full year ended December 31, 2011, and provided highlights of recent key developments.
14y agoHGSIINSERTING and REPLACING Human Genome Sciences to Sponsor Conference Call to Discuss Fourth-Quarter and Full-Year 2011 Financial ResultsBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Insert after first paragraph: The conference call will be hosted by senior management and will be held on Monday, February 27, 2012 at 4:30 pm Eastern time.
14y agoHGSIHuman Genome Sciences Invites Investors to Listen to Webcast of Presentation at Leerink Swann ConferenceBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the Leerink Swann 2012 Global Healthcare Conference will be webcast and may be accessed at www.hgsi.com.
14y agoHGSIHuman Genome Sciences Invites Investors to Listen to Webcast of Presentation at BIO CEO and Investor ConferenceBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the 14th Annual BIO CEO & Investor Conference will be webcast and may be accessed at www.hgsi.com.
14y agoHGSIZeldes & Haeggquist, LLP Announces Investigation of Human Genome Sciences, Inc. (HGSI)Business WireSAN DIEGO--(BUSINESS WIRE)--Zeldes & Haeggquist, LLP, a shareholder and consumer rights litigation firm, has commenced an investigation into Human Genome Sciences, Inc. (NASDAQ: HGSI) to determine whether it has violated securities laws by issuing false and misleading statements to its shareholders between July 20, 2009 and November 11, 2010.
14y agoHGSIHuman Genome Sciences Reports Progress with Commercialization of BENLYSTA® and Announces 2012 Goals at JPMorgan Healthcare ConferenceBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) will today announce its priority goals for 2012 and report on progress with the commercialization of BENLYSTA® (belimumab), the first approved drug for systemic lupus in 56 years, during a presentation this afternoon by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 30t ...
14y agoHGSIHuman Genome Sciences Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare ConferenceBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the J.P. Morgan 30th Annual Healthcare Conference will be webcast and may be accessed at www.hgsi.com.
14y agoHGSIRobbins Umeda LLP Announces an Investigation of Human Genome Sciences, Inc.Business WireSAN DIEGO--(BUSINESS WIRE)--Shareholder rights firm Robbins Umeda LLP is investigating possible breaches of fiduciary duty and other violations of the law by certain officers and directors at Human Genome Sciences, Inc. (NASDAQ: HGSI). Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Gregory E. Del Gaizo at (800) 350-6003, gdelga ...
14y agoHGSIHuman Genome Sciences and GlaxoSmithKline Initiate Phase 3 Trial of Belimumab (BENLYSTA®) Administered Subcutaneously in Subjects with Systemic Lupus ErythematosusBusiness WireROCKVILLE, Md. & LONDON--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that dosing has been initiated in BLISS-SC, a new Phase 3 trial to evaluate the efficacy, safety and tolerability of BENLYSTA® (belimumab) administered subcutaneously (SC) once-weekly to autoantibody-positive adults with active systemic lupus erythematosus (SLE).
14y agoHGSIHuman Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank ConferenceBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the 2011 Deutsche Bank BioFEST Conference will be webcast and may be accessed at www.hgsi.com.
14y agoHGSIHuman Genome Sciences Invites Investors to Listen to Webcast of Presentation at Piper Jaffray ConferenceBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the Piper Jaffray 23rd Annual Health Care Conference will be webcast and may be accessed at www.hgsi.com.
15y agoHGSIHuman Genome Sciences Invites Investors to Listen to Webcast of Presentation at Credit Suisse ConferenceBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the 2011 Annual Credit Suisse Health Care Conference will be webcast and may be accessed at www.hgsi.com.
15y agoHGSIHuman Genome Sciences Completes Offering of $494.5 Million of Convertible Senior NotesBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the completion of its offering and sale of $494.5 million in aggregate principal amount of 3.00% Convertible Senior Notes due 2018 pursuant to a registration statement filed with the Securities and Exchange Commission. This includes the exercise in full by the underwriters of their option to purchase $64.5 ...
15y agoHGSIHuman Genome Sciences Announces Multiple Abstracts Related to BENLYSTA® and Systemic Lupus Erythematosus to Be Presented at the 2011 ACR/ARHP Annual Scientific MeetingBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that several abstracts related to BENLYSTA® (belimumab) and systemic lupus erythematosus (SLE) will be presented at the annual meeting of the American College of Rheumatology/ Association of Rheumatology Health Professionals, being held in Chicago, IL from November 4 to November 9, 2011. A total of 13 abstr ...
15y agoHGSIHuman Genome Sciences Announces Exercise of Option to Purchase Additional Notes for Total Convertible Notes Issuance of $494.5 MillionBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the exercise in full of the underwriter’s option to purchase an additional $64.5 million principal amount of its Convertible Senior Notes due 2018 in connection with its public offering of the notes on November 2, 2011, for a total offering size of $494.5 million. Citigroup is acting as the underwriter, and ...
15y agoHGSIHuman Genome Sciences Prices $430 Million Convertible Notes IssuanceBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has priced an underwritten public offering of $430 million aggregate principal amount of Convertible Senior Notes due 2018, which was upsized from the previously announced $400 million offering. Citigroup is acting as the underwriter. The underwriter has the option to purchase up to an additional $6 ...
15y agoHGSIHuman Genome Sciences Announces Offering of Convertible NotesBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of its Convertible Senior Notes due 2018. The notes will be convertible, under certain circumstances, into cash, shares of the company’s common stock, or a combination, at the company’s election. The inte ...
15y agoHGSIHuman Genome Sciences Announces Third Quarter 2011 Financial Results and Key DevelopmentsBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial results for the quarter ended September 30, 2011, and provided highlights of recent key developments.
15y agoHGSIHuman Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2011 Financial ResultsBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it will sponsor a conference call to discuss its financial results for the quarter ended September 30, 2011. These results are expected to be released on Tuesday, October 25, 2011, after the capital markets close.
15y agoHGSIHuman Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS ConferenceBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the UBS Global Life Sciences Conference will be webcast and may be accessed at www.hgsi.com.
15y agoHGSIHuman Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bank of America Merrill Lynch ConferenceBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the Bank of America Merrill Lynch Healthcare Conference will be webcast and may be accessed at www.hgsi.com.
15y agoHGSIHuman Genome Sciences Invites Investors to Listen to Webcast of Presentation at Morgan Stanley ConferenceBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the Morgan Stanley Global Healthcare Conference will be webcast and may be accessed at www.hgsi.com.
15y agoHGSIHuman Genome Sciences Invites Investors to Listen to Webcast of Presentation at Baird ConferenceBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at Baird's 2011 Health Care Conference will be webcast and may be accessed at www.hgsi.com.
15y agoHGSIHuman Genome Sciences Names Craig C. Parker Senior Vice President, Strategy and Corporate DevelopmentBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Craig C. Parker has joined the company as Senior Vice President, Strategy and Corporate Development. He will report directly to H. Thomas Watkins, President and Chief Executive Officer, and will serve as a member of the Management Committee of the Company.
15y agoHGSIHuman Genome Sciences Announces Second Quarter 2011 Financial Results and Key DevelopmentsBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial results for the quarter ended June 30, 2011, and provided highlights of recent key developments.
15y agoHGSIHuman Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2011 Financial ResultsBusiness WireROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it will sponsor a conference call to discuss its financial results for the quarter ended June 30, 2011. These results are expected to be disclosed on Thursday, July 21, 2011, after the capital markets close.
15y agoHGSIGlaxoSmithKline and Human Genome Sciences Receive European Authorization for BENLYSTA® (Belimumab)Business WireLONDON & ROCKVILLE, Md.--(BUSINESS WIRE)--GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that the European Commission (EC) has granted marketing authorization for BENLYSTA® (belimumab) 10mg/kg as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus (SLE), with a high degree of disease activity (e.g. positive anti-d ...